Article Sidebar
Views PDF: 226
OUTCOMES OF DECITABINE MONOTHERAPY FOR ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS IN THE NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION DURING 2019-2021
Main Article Content
Abstract
Background: Deciding initial treatment for elderly leukemia patients (≥60 years of age) require determination of a few prognosis factors, such as age, cytogenetic and molecular genetic abnormalities, performance status and comorbidities. Decitabine is a new drug which being widely used as a therapeutic option for elderly acute myeloid leukemia patients. Objective: evaluate the efficacy of Decitabine as a monotherapy in elderly patients with acute myeloid leukemia. Materials and methods: Prospective intervention study without control group. 40 AML patients in NIHBT were enrolled and treated with Decitabine monotherapy from 2019 to 2021. Results and conclusions: overall response rate was 32.5%, 17.5% achieved complete remission, 5% achieved partial remission and 10% had hematologic improvements. Myelosuppression is the major toxicity.
Article Details
Keywords
Acute myeloid leukemia, AML, Elderly, Decitabine
References
2. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2012;30(21):2670-2677. doi:10.1200/JCO.2011.38.9429.
3. Park H, Chung H, Lee J, et al. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia. Yonsei Med J. 2017;58(1):35-42. doi:10.3349/ ymj.2017.58.1.35.
4. Yoo KH, Cho J, Han B, et al. Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults. PLoS One. 2020;15(8). doi:10.1371/journal.pone.0235503.
5. Phạm Quang Vinh, Nguyễn Hà Thanh, et al. Bài giảng sau đại học Huyết học - Truyền máu tập 1. Nhà xuất bản y học; 2019.
6. Cashen AF, Schiller GJ, O’Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556-561. doi:10.1200/JCO.2009.23.9178.